. Author manuscript; available in PMC: 2020 Mar 1.

Published in final edited form as: Pediatr Infect Dis J. 2019 Mar;38(3):302–307. doi: 10.1097/INF.0000000000002055

TABLE 2.

Frequency and duration of antibiotic use

Antibiotics	≤1500 g (n = 253)		>1500 g (n = 155)
Antibiotics	Patients that received antibiotic n (%)	Treatment duration, daysmedian (IQR)	Patients that received antibiotic n (%)	Treatment duration, daysmedian (IQR)
Gent/Amika^*	101 (39.9%)	5 (3 – 8)	26 (16.7%)	4 (7 – 10)
Ampicillin^*	95 (37.5%)	3 (2 – 6)	20 (12.9%)	4 (3 – 7)
Vancomycin^*	100 (39.5%)	13 (8 – 20)	15 (9.7%)	6 (3 – 25)
Imipenem^*	64 (25.3%)	10 (6 – 14)	9 (5.8%)	8 (4 – 12)
Meropenem^*	46 (18.2%)	10 (6 – 17)	5 (3.2%)	11 (7 – 14)
Ceftazidime^*	32 (12.6%)	6 (4 – 9)	10 (6.5%)	6 (5 – 10)
Metronidazole^*	21 (8.3%)	8 (3 – 14)	1 (0.6%)	23
Cefotaxime	18 (7.1%)	3.5 (2 – 7)	4 (2.6%)	2.5 (2 – 5)
Ciprofloxacin	16 (6.3%)	6.5 (5 – 10)	1 (0.6%)	12
Pip/Tazo^*	15 (5.9%)	8 (3 – 19)	0	-
Cefepime^*	10 (4.0%)	7 (5 – 8)	2 (1.3%)	5.5 (1 – 10)
Linezolid^*	8 (3.2%)	14.5 (5 – 21)	0	-

There was no significant difference in treatment duration between BW groups for all antibiotics analyzed.

p<0.05 when comparing number of patients that received antibiotic between both BW groups